Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, capsaicin (Qutenza®) cannot be endorsed for use within NHS Wales for the treatment of peripheral neuropathic pain in diabetic adults either alone or in combination with other medicinal products for pain. Capsaicin (Qutenza®) is being considered for suitability for AWMSG reassessment by the AWMSG Scrutiny Panel at their meeting on 18/12/2025. |
||
|
||
Medicine details |
||
| Medicine name | capsaicin (Qutenza®) | |
| Formulation | 179 mg cutaneous patch | |
| Reference number | 2889 | |
| Indication | Treatment of peripheral neuropathic pain in diabetic adults either alone or in combination with other medicinal products for pain |
|
| Company | Astellas Pharma Ltd | |
| BNF chapter | Central nervous system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 09/12/2015 | |
| Further information Capsaicin (Qutenza®) is being considered for suitability for AWMSG reassessment by the AWMSG Scrutiny Panel at their meeting on 18/12/2025. |
||